August 2019 cover_right.jpg
 

ISSN: 2424-810X (online)

ISSN: 2382-6533 (print)

Journal abbreviation: J Clin Transl Res

Publication frequency: continuously before 2021; bi-monthly after 2021 

Article processing charges (APC): USD 1000 (per 9am CET, August 1, 2022)

Publishing model: Open access

Established: 2015

Overall rejection rate: 47% (updated in May 2022)

Publisher: Whioce Publishing

JCTR Google Scholar profile

News

Dr. Roberto Gramignoli joins JCTR translational editorial board

September 28, 2022

Dr. Gramignoli's primary interest has always been regenerative medicine, including cell and gene therapies, as an alternative option to treat life-threatening and chronic diseases. 

Working with his Mentor - Dr. Strom, allowed Dr. Gramignoli to develop and validate new treatments for acute and congenital liver disorders, such as human hepatocyte transplant as a bridge or an alternative to orthotopic liver transplantation. Their laboratory was the first facility to be approved for the isolation of human hepatocytes for clinical transplants, and this allowed them to transplant hepatocytes in patients with metabolic liver diseases. 

Since the main limiting factor in the use of human hepatocytes is the availability of functional cells, Dr. Gramignoli focused his attention on alternative sources of human cells, such as non-heart-beating or fetal and neonatal donors. Furthermore, he studied and validated the concept of “domino liver cell transplantation”, and using a novel animal model (FRG mouse) supporting human liver cell repopulations, his team is actively repopulating livers with human cells aimed to generate new preclinical tools for orphan human diseases. Moreover, they evaluated different pluripotent and multipotent stem cells, with the greatest results obtained by transplantation of epithelial stem cells isolated from full-term amnion membrane (human placenta). Encouraged by the lack of tumorigenicity for these allogenic perinatal stem cells, Dr. Gramignoli's team proved correction in inborn error disease preclinical models, and a supporting therapy in acute/chronic disorders. Preclinical data suggest that, although not the patient’s own cells, amnion epithelial cells survive long-term and do not require immunosuppression. These preclinical results stimulated the creation of perinatal stem cell bank for clinical purposes and phase I/IIa clinical trial. 

Dr. Gramignoli's publication record can be found here.

Prof. Khawaja Husnain Haider joins JCTR translational editorial board

September 21, 2022

Khawaja Husnain Haider is currently working as a full professor and chairman of Basic Sciences in Sulaiman AlRajhi University (Medical Program), Saudi Arabia.

Prof. Haider has published 4 books, more than 275 research papers, book chapters, and conference abstracts. His current interest, based on his extensive research experience in stem cells and gene therapy, either alone or as a combined approach, is to use stem cells and DNA as drugs in regenerative medicine. Prof. Haider's publication record can be found here.

pubmed-logo-blue.png
peking-university.png
google-scholar.png
ckni.png
cas-logo.png